Examkin

Question

Difficulty: HardRheumatology and Immunology

Match each biologic disease-modifying antirheumatic drug (bDMARD) with its specific mechanism of action and the most characteristic clinical caveat or adverse effect associated with its use.

  • RituximabDepletes CD20-positive B lymphocytes; carries a black-box warning for hepatitis B virus reactivation and rare cases of progressive multifocal leukoencephalopathy.
  • TocilizumabInhibits interleukin-6 (IL-6) receptor signaling; associated with dose-dependent dyslipidemia, transaminitis, and an increased risk of lower gastrointestinal perforation.
  • AbataceptBinds to CD80 and CD86 on antigen-presenting cells to block T-cell costimulation; generally avoided in patients with severe chronic obstructive pulmonary disease due to respiratory exacerbations.
  • AnakinraCompetitively inhibits the interleukin-1 (IL-1) receptor; characterized by a short half-life requiring daily subcutaneous administration, commonly used in adult-onset Still disease.
  • SecukinumabDirectly neutralizes interleukin-17A (IL-17A); highly efficacious for spondyloarthropathies but should be avoided in patients with a history of inflammatory bowel disease due to the risk of disease exacerbation.

Answer

Rituximab depletes CD20 and risks HBV reactivation; Tocilizumab inhibits IL-6 and risks GI perforation; Abatacept blocks CD80/86 and risks COPD exacerbation; Anakinra inhibits IL-1 and requires daily injections; Secukinumab neutralizes IL-17A and risks IBD exacerbation.
Each biologic DMARD has a distinct mechanism of action and a unique adverse effect profile that dictates pre-treatment screening and patient selection. Rituximab (anti-CD20) risks HBV reactivation. Tocilizumab (anti-IL-6R) is associated with dyslipidemia and GI perforations. Abatacept (CTLA-4-Ig) can exacerbate COPD. Anakinra (IL-1RA) has a short half-life requiring daily dosing. Secukinumab (anti-IL-17A) can precipitate or worsen inflammatory bowel disease.

Step-by-Step Solution

1
Analyze the mechanism and adverse effects of Rituximab.
Rituximab targets CD20 on B cells. A classic and severe complication is hepatitis B reactivation, necessitating prior screening.
Identifying the target and its black-box warnings isolates the correct match.
2
Analyze the mechanism and adverse effects of Tocilizumab.
Tocilizumab targets the IL-6 receptor. It is uniquely associated with dyslipidemia and an increased risk of lower GI perforation, particularly in patients with diverticular disease.
IL-6 blockade has distinct metabolic and tissue-healing effects.
3
Analyze the mechanism and adverse effects of Abatacept.
Abatacept blocks T-cell costimulation via CD80/86. It has a specific warning for use in patients with underlying COPD due to increased respiratory exacerbations.
Costimulation blockade has specific pulmonary caveats.
4
Analyze the mechanism and adverse effects of Anakinra.
Anakinra is an IL-1 receptor antagonist. Its recombinant protein structure gives it a short half-life, requiring daily dosing.
Dosing frequency is a unique clinical caveat among biologics.
5
Analyze the mechanism and adverse effects of Secukinumab.
Secukinumab targets IL-17A. Because IL-17 maintains gut mucosal integrity, its blockade can induce or worsen Crohn disease and ulcerative colitis.
Understanding the physiological role of IL-17 explains its contraindication in IBD.

Key Concept

The mechanisms of action and highly specific adverse effect profiles of biologic disease-modifying antirheumatic drugs (bDMARDs).
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic